Monitoring of KRAS-mutated circulating tumor DNA in pancreatic cancer patients with neoadjuvant treatment

Monitoring of KRAS-mutated cell-free DNA in pancreatic cancer patients with neoadjuvant treatment - Monitoring of ctDNA in pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041786

Enrollment

Registered

2020-11-01

Start date

2020-11-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic ductal adenocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Histologically confirmed pancreatic ductal adenocarcinoma -Planned for neoadjuvant treatment -ECOG performance status 0 or 1 -No history of any treatment for pancreatic ductal adenocarcinoma

Exclusion criteria

Exclusion criteria: -Administration of immunosuppressive agent -Severe organ dysfunction -Severe infection -Pregnancy -Double cancer -Investigator judgement that the patient should not participate for any reason.

Design outcomes

Primary

Measure	Time frame
Disease free survival on 6 months after surgery	—

Secondary

Measure	Time frame
-Overall survival -Disease free survival -R0 resection -Serum CA19-9 -Pathological response	—

Countries

Japan

Contacts

Public ContactSachiyo Shirakawa

Kobe University Hospital Hepato-Biliary-Pancreatic Surgery

sachiyo@pearl.kobe-u.ac.jp078-382-6302

Outcome results